HC Wainwright Has Bearish Estimate for ETON Q1 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at HC Wainwright dropped their Q1 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.09 per share for the quarter, down from their previous estimate of $0.12. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals' Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Price Performance

Shares of Eton Pharmaceuticals stock traded down $0.44 during trading on Friday, hitting $10.02. The stock had a trading volume of 538,152 shares, compared to its average volume of 94,962. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $11.11. The firm has a market cap of $258.92 million, a P/E ratio of -45.55 and a beta of 1.25. The business has a fifty day moving average of $7.40 and a two-hundred day moving average of $4.98.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Thompson Siegel & Walmsley LLC bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $420,000. Aristides Capital LLC bought a new position in Eton Pharmaceuticals in the 2nd quarter valued at $658,000. Acadian Asset Management LLC boosted its stake in Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company's stock worth $585,000 after purchasing an additional 18,898 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock worth $350,000 after purchasing an additional 41,469 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth about $3,095,000. 27.86% of the stock is currently owned by institutional investors.

Insider Activity at Eton Pharmaceuticals

In related news, major shareholder Opaleye Management Inc. bought 57,500 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The stock was purchased at an average cost of $4.65 per share, for a total transaction of $267,375.00. Following the purchase, the insider now directly owns 2,660,000 shares in the company, valued at $12,369,000. This trade represents a 2.21 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders acquired 85,600 shares of company stock valued at $462,674. Insiders own 14.89% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.